chemotherapy only

PreclinicalSmall molecule

SSamsung Medical Center

chemotherapy only is one of 63 small molecule programs targeting Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Colorectal CancerActive, not recruiting

LymphomaPreclinical

Active, not recruiting

Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Not yet recruiting

Neoadjuvant Therapy

NCT06503042

Clinical

Trials by Indication[1]

Lymphoma1 trial

Samsung Medical Center-Lymphoma Cohort Study

Completed·SSamsung Medical Center·N/A·NCT00822731·953 enrolled

Colorectal Cancer1 trial

Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer

Completed·UUniversity of Leicester·Phase 1/2·NCT01490996·41 enrolled

Second-line Treatment1 trial

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

Terminated·CCentre Francois Baclesse·Phase 3·NCT02178397·6 enrolled

Adjuvant1 trial

Adjuvant CCRT vs CT in Minimal N2 NSCLC

Completed·SSamsung Medical Center·Phase 2·NCT01066234·17 enrolled

Neoadjuvant Therapy1 trial

A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC

Not yet recruiting·TTang-Du Hospital··NCT06503042·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for chemotherapy only. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chemotherapy only compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chemotherapy only. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Samsung Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSamsung Medical Center

chemotherapy only

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Lymphoma1 trial

Colorectal Cancer1 trial

Second-line Treatment1 trial

Adjuvant1 trial

Neoadjuvant Therapy1 trial

References

Drug Info

Quick Facts

Related News